The open-label phase of the GRACE trial showed significant improvements in systolic and diastolic blood pressure. Can you elaborate on how relacorilant’s mechanism of action contributes to these results and its potential advantages over existing hypertension treatments for Cushing’s syndrome patients?

Relacorilant demonstrated clinically meaningful improvements in glucose metabolism, including reductions in HbA1c and fasting glucose levels. How do these findings impact the overall management of hyperglycemia in Cushing’s syndrome, and what implications might this have for patients with concurrent diabetes?

The trial results indicated that relacorilant was well-tolerated with no significant safety concerns such as cortisol-induced hypokalemia or endometrial hypertrophy. How do these safety outcomes compare to current treatment options, and what does this mean for long-term patient management?

Significant improvements were observed in the Cushing’s Quality of Life score. From a clinical perspective, how do these improvements translate into real-world benefits for patients, and what key factors should be considered when evaluating patient-reported outcomes in Cushing’s syndrome?

The data showed reductions in body weight and waist circumference among patients. How might these physical changes influence the overall health and risk profile of Cushing’s syndrome patients, and what role does relacorilant play in achieving these outcomes?

Improvements in cognitive function were noted through the Trail Making Test. Can you discuss the significance of these findings and how relacorilant might affect cognitive symptoms commonly associated with Cushing’s syndrome?

Patients experienced improvements across a wide range of Cushing’s syndrome symptoms. How does relacorilant’s selective cortisol modulation contribute to these broad therapeutic effects, and what does this mean for the future treatment landscape of hypercortisolism?

Given the positive open-label results, what are your expectations for the randomized withdrawal phase of the GRACE trial? How do you foresee relacorilant shaping the standard of care for Cushing’s syndrome moving forward, and what additional research or clinical trials might be needed to further validate its efficacy and safety?

The Phase 3 GRACE trial met its primary endpoint with relacorilant showing a significant reduction in the loss of blood pressure control compared to placebo. Can you explain the clinical significance of this finding for patients with hypercortisolism (Cushing’s syndrome), and how it impacts current treatment paradigms?

During the open-label phase of the GRACE study, patients exhibited meaningful improvements in hypertension and hyperglycemia. Could you elaborate on how relacorilant achieves these effects and the potential benefits this offers to patients managing multiple symptoms of Cushing's syndrome?

Relacorilant was reported to be well-tolerated in both phases of the GRACE trial with no significant differences in adverse events between the treatment and placebo groups. What does this safety profile imply for the long-term use of relacorilant, and how might it influence its adoption in clinical practice?